Antimicrobial Resistance Cost in Two Ghanaian Hospitals

By Staff Writer

January 8, 2024

Antimicrobial Resistance Costs: A Burden on Healthcare Providers

Antimicrobial resistance (AMR) and antimicrobial resistance costs are a global challenge with significant implications for healthcare providers. A recent study conducted in two public tertiary hospitals in Ghana, a lower-middle-income setting, quantified the healthcare provider costs (HPCs) due to AMR using both aggregated ingredient costing and step-down costing approaches. The results reveal that AMR patients demand more time and resources from healthcare providers than patients infected with susceptible bacteria or uninfected patients.

The Direct Impact of AMR on Hospitals

The study found that if AMR could be avoided, the extra 5 bed days allocated for treating an estimated 740 AMR patients annually at both hospitals would free up 3700 bed days, allowing for the admission of an additional 451 patients. Moreover, doctors spend an extra 7 hours at Hospital 1 and 3 hours at Hospital 2 caring for each AMR patient admitted to the hospital within a 30-day data collection period.

The Cost of AMR

The research also highlighted the variation in costs due to AMR causative pathogens. For instance, treating each patient with MRSA bloodstream infections at Hospital 1 was approximately 33% higher than treating K. pneumoniae and 16% higher than E. coli bloodstream infections resistant to 3GC. The provider cost of treating AMR was highest for the medical emergency unit due to its limited capacity to treat patients with severe and emergency health conditions compared to the general medical unit.

Mitigating AMR: A Matter of Urgency

The findings underscore the urgent need for healthcare providers and policymakers to focus on AMR mitigation measures. Such measures may include general infection prevention and control, effective antibiotic regulation, and adherence to WHO’s access, watch and reserve (AWaRe) recommendation for antibiotic prescription and therapy. The study also advocates for demand-driven strategies, such as point-of-care education regarding antibiotic use and resistance’s health and economic implications, and supply-driven interventions like hospital-wide antibiotic restriction policy implementation.

In conclusion, AMR imposes significant costs on healthcare providers, particularly in lower-middle-income settings. These costs can be avoided through a myriad of infection prevention and control strategies, thus making a strong case for investment in AMR mitigation strategies.

Reference url

Recent Posts

Mental Health Policy Integration: A Cross-Sector Imperative for Well-being and Productivity

By João L. Carapinha

July 31, 2025

The purpose of this update is to review a recent Lancet editorial (linked below) on mental health policy integration in public policy frameworks. The article “Mental health in all policies” emphasizes that mental health influences individual well-being, societal cohesion, and economic productivit...
Novartis Gains Approval for Groundbreaking Malaria Treatment for Infants

By Rene Pretorius

July 30, 2025

In this article we review Swissmedic's approval of Novartis' Coartem Baby. It is the first malaria treatment for infants under 4.5 kilograms. This novel formulation addresses a critical gap in antimalarial care. Existing treatments were unsuitable due to dosing and metabolism concerns in young in...
ViiV Healthcare Licensing: Expanding Access to Long-Acting HIV Treatment in Low-Income Countries
ViiV Healthcare has expanded its voluntary licensing agreement with the Medicines Patent Pool. The update now includes access to long-acting injectable cabotegravir (CAB LA) for HIV treatment. This allows generic manufacturers to supply the therapy in 133 low- and middle-income countries (LMICs)....